Lupin Bioresearch Center Receives Zero Observations from U.S. FDA After Successful Inspection and Assessment

Global pharma major Lupin Limited announced that the United States Food and Drug Administration (U.S. FDA) has completed an onsite clinical inspection from November 3 to November 6, 2025, at its Bioresearch Centre in Pune with zero 483 observations. A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations. This successful outcome is a testament to Lupin's ongoing commitment to quality and compliance, and the company remains focused on improving the lives of patients globally.